The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Revenue | 133,927 |
| Less cost of sales | 49,654 |
| Gross profit | 84,273 |
| General and administrative | 29,375 |
| Sales and marketing | 45,512 |
| Research and development | 2,102 |
| Interest expense | 3,671 |
| Interest income | 94 |
| Unrealized foreign currency translation loss (gain) | -60 |
| Gain on divestiture | 3,281 |
| Other (income) expense | 73 |
| Provision for income taxes current and deferred | 2,028 |
| Net income (loss) | 4,973 |
| Depreciation and amortization | 5,223 |
| Non-cash interest | 537 |
| Loss (gain) on sale of fixed assets | -251 |
| Stock-based compensation | 2,892 |
| Provision for reserve on accounts receivable | 1,404 |
| Provision for excess and obsolete inventory | 3,669 |
| Gain on divestiture | 3,281 |
| Other | -76 |
| Trade accounts receivable | 591 |
| Inventories | 1,999 |
| Prepaid and other assets | 1,537 |
| Accounts payable | -3,117 |
| Accrued liabilities | 4,198 |
| Net cash provided by (used in) operating activities | 12,546 |
| Purchases of property and equipment | 2,382 |
| Proceeds from sale of fixed assets | 232 |
| Proceeds from divestiture | 10,049 |
| Net cash provided by (used in) investing activities | 7,899 |
| Borrowings on line of credit | 100,066 |
| Repayments on line of credit | 101,329 |
| Payments on long-term debt | 8,000 |
| Payments on financing leases | 67 |
| Proceeds from private placement, net of issuance costs | -65 |
| Debt issuance costs | 49 |
| Payment of taxes from withholding of common stock upon vesting and settlement of restricted stock units | 126 |
| Net cash (used in) provided by financing activities | -9,570 |
| Effect of exchange rate changes on cash and cash equivalents and restricted cash | 232 |
| Net change in cash and cash equivalents and restricted cash | 11,107 |
| Cash and cash equivalents and restricted cash at beginning of year | 6,221 |
| Cash and cash equivalents and restricted cash at end of year | 17,328 |
Xtant Medical Holdings, Inc. (XTNT)
Xtant Medical Holdings, Inc. (XTNT)